158 related articles for article (PubMed ID: 12572995)
21. Deferasirox for transfusion-related iron overload: a clinical review.
Lindsey WT; Olin BR
Clin Ther; 2007 Oct; 29(10):2154-66. PubMed ID: 18042472
[TBL] [Abstract][Full Text] [Related]
22. Deferasirox AUC efficacy cutoff and role of pharmacogenetics.
Allegra S; Cusato J; De Francia S; Massano D; Piga A; D'Avolio A
Eur J Clin Pharmacol; 2016 Sep; 72(9):1155-7. PubMed ID: 27193993
[No Abstract] [Full Text] [Related]
23. Ability of deferasirox to bind iron during measurement of iron.
Lebitasy M; Ampe E; Hecq JD; Karmani L; Nick H; Galanti L
Clin Chem Lab Med; 2010 Mar; 48(3):427-9. PubMed ID: 20170398
[No Abstract] [Full Text] [Related]
24. Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial.
Wood JC; Glynos T; Thompson A; Giardina P; Harmatz P; Kang BP; Paley C; Coates TD
Haematologica; 2011 Jul; 96(7):1055-8. PubMed ID: 21393329
[TBL] [Abstract][Full Text] [Related]
25. Deferasirox does not induce QT/QTc-prolongation in healthy subjects.
Sechaud R; Dumortier T; Balez S
Int J Clin Pharmacol Ther; 2009 May; 47(5):321-7. PubMed ID: 19473594
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration.
Lu MY; Wang N; Wu WH; Lai CW; Kuo PH; Chiang PH; Lin KH; Wu TH
Clin Ther; 2015 Aug; 37(8):1751-60. PubMed ID: 26093827
[TBL] [Abstract][Full Text] [Related]
27. Comparison of iron chelator efficacy in iron-overloaded beagle dogs and monkeys (Cebus apella).
Bergeron RJ; Wiegand J; Weimar WR; Lindstrom TC; Fannin TL; Ratliff-Thompson K
Comp Med; 2004 Dec; 54(6):664-72. PubMed ID: 15679265
[TBL] [Abstract][Full Text] [Related]
28. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
Chang HH; Lu MY; Liao YM; Lin PC; Yang YL; Lin DT; Chiou SS; Jou ST; Lin KH; Chang TT
Pediatr Blood Cancer; 2011 Mar; 56(3):420-4. PubMed ID: 21072825
[TBL] [Abstract][Full Text] [Related]
29. Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia.
Allegra S; De Francia S; Longo F; Massano D; Cusato J; Arduino A; Pirro E; Piga A; D'Avolio A
Biomed Pharmacother; 2016 Dec; 84():1510-1512. PubMed ID: 27881236
[TBL] [Abstract][Full Text] [Related]
30. Pyridoxal isonicotinoyl hydrazone and its analogues.
Buss JL; Hermes-Lima M; Ponka P
Adv Exp Med Biol; 2002; 509():205-29. PubMed ID: 12572996
[No Abstract] [Full Text] [Related]
31. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.
Shashaty G; Frankewich R; Chakraborti T; Choudary J; Al-Fayoumi S; Kacuba A; Castillo S; Robie-Suh K; Rieves D; Weiss K; Pazdur R
Oncology (Williston Park); 2006 Dec; 20(14):1799-1806, 1811; discussion 1811-13, 1817. PubMed ID: 17263129
[TBL] [Abstract][Full Text] [Related]
32. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin.
Hasinoff BB; Patel D; Wu X
Free Radic Biol Med; 2003 Dec; 35(11):1469-79. PubMed ID: 14642395
[TBL] [Abstract][Full Text] [Related]
33. Deferasirox: An effective once-daily orally active iron chelator.
Porter JB
Drugs Today (Barc); 2006 Oct; 42(10):623-37. PubMed ID: 17136223
[TBL] [Abstract][Full Text] [Related]
34. The oral chelator deferasirox--a new perspective for patients with iron overload.
Fischer R
Haematologica; 2006 Jul; 91(7):865A. PubMed ID: 16818263
[No Abstract] [Full Text] [Related]
35. Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury.
Jansová H; Macháček M; Wang Q; Hašková P; Jirkovská A; Potůčková E; Kielar F; Franz KJ; Simůnek T
Free Radic Biol Med; 2014 Sep; 74():210-21. PubMed ID: 24992833
[TBL] [Abstract][Full Text] [Related]
36. Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen.
Galanello R; Piga A; Cappellini MD; Forni GL; Zappu A; Origa R; Dutreix C; Belleli R; Ford JM; Rivière GJ; Balez S; Alberti D; Séchaud R
J Clin Pharmacol; 2008 Apr; 48(4):428-35. PubMed ID: 18281442
[TBL] [Abstract][Full Text] [Related]
37. Transport of iron chelators and chelates across MDCK cell monolayers: implications for iron excretion during chelation therapy.
Huang XP; Thiessen JJ; Spino M; Templeton DM
Int J Hematol; 2010 Apr; 91(3):401-12. PubMed ID: 20213118
[TBL] [Abstract][Full Text] [Related]
38. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
Ladis V; Berdousi H; Gotsis E; Kattamis A
Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
[TBL] [Abstract][Full Text] [Related]
39. Expanding the Therapeutic Potential of the Iron Chelator Deferasirox in the Development of Aqueous Stable Ti(IV) Anticancer Complexes.
Loza-Rosas SA; Vázquez-Salgado AM; Rivero KI; Negrón LJ; Delgado Y; Benjamín-Rivera JA; Vázquez-Maldonado AL; Parks TB; Munet-Colón C; Tinoco AD
Inorg Chem; 2017 Jul; 56(14):7788-7802. PubMed ID: 28644630
[TBL] [Abstract][Full Text] [Related]
40. Deferasirox Novartis.
Barton JC
Curr Opin Investig Drugs; 2005 Mar; 6(3):327-35. PubMed ID: 15816510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
